Drug Search Results

Mitiglinide

Alternative Names: mitiglinide, kad-1229
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Voltage-Gated Potassium Channel Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: China | Egypt | Japan | Taiwan | Thailand

Approved Indications: None

Known Adverse Events: None

Company: Kissei Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mitiglinide

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Type 2 Diabetes

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
CTR20131966	P2	Active, not recruiting	Type 2 Diabetes	None
CTR20132647	P2	Recruiting	Type 2 Diabetes	None

Recent News Events

Date	Type	Title
04/01/2024	PubMed	Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial.
01/01/2024	PubMed	Preparation, in vitro and in vivo evaluation of a novel mitiglinide microemulsions.
09/04/2023	PubMed	The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching.
03/31/2020	News Article	Uni-Bio Science Group Limited 2019 Annual Results Turnover Increased by 54.9% YoY to HK$209.4 Million Recording EBITDA of HK$28.4 Million Achieved Significant Progress Towards Pipeline Product with 2 Product Launches Expected in 2020

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions